Compounds > bmy 21502
Page last updated: 2024-12-07

bmy 21502

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BMY 21502: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129930
CHEMBL ID4762661
SCHEMBL ID194426
MeSH IDM0176756

Synonyms (17)

Synonym
bms-181168
bmy-21502
bmy 21502
1-[[1-[2-(trifluoromethyl)pyrimidin-4-yl]piperidin-4-yl]methyl]pyrrolidin-2-one
123259-91-6
unii-lxs7fnv64o
1-(1-(2-fluoromethyl)-4-pyrimidinyl)-4-piperidinylmethyl-2-pyrrolidinone
2-pyrrolidinone, 1-((1-(2-(trifluoromethyl)-4-pyrimidinyl)-4-piperidinyl)methyl)-
lxs7fnv64o ,
SCHEMBL194426
1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone
DTXSID80153922
bms 181168
1-((1-(2-(trifluoromethyl)-4-pyrimidinyl)-4-piperidinyl)methyl)-2-pyrrolidinone
1-((1-(2-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)methyl)pyrrolidin-2-one
CHEMBL4762661
AKOS040750881

Research Excerpts

Overview

BMY 21502 is a novel pyrrolidinone nootropic with demonstrated ability to reverse electroconvulsively induced amnesia in rodents.

ExcerptReferenceRelevance
"BMY 21502 is a novel pyrrolidinone nootropic with demonstrated ability to reverse electroconvulsively induced amnesia in rodents. "( Effect of BMY 21502 on acquisition of shape discrimination and memory retention in monkey.
Fitten, LJ; Hanna, JA; Menon, MK; Perryman, KM, 1990)		2.12

Toxicity

ExcerptReferenceRelevance
" Twelve (35%) patients who received BMY 21,502 withdrew from the study, 8 (24%) due to adverse events."( The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease.
Cutler, NR; Hironaka, DY; Reich, LA; Seifert, RD; Shrotriya, RC; Sramek, JJ; Veroff, AE, 1993)		0.29

Dosage Studied

ExcerptRelevanceReference
" A dose-response relationship was established for the acquisition of shape discrimination for each monkey."( Effect of BMY 21502 on acquisition of shape discrimination and memory retention in monkey.
Fitten, LJ; Hanna, JA; Menon, MK; Perryman, KM, 1990)		0.68
" Following oral dosing of a solution of BMY-21502 (0."( Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.
Kaul, S; Srinivas, N, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.86 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
idebenone
[no description available]		1.98101,4-benzoquinones;
primary alcohol		antioxidant;
ferroptosis inhibitor
oxiracetam
oxiracetam: structure in first source		1.9810organonitrogen compound;
organooxygen compound
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		6.9710organonitrogen compound;
organooxygen compound
potassium cyanide
[no description available]		1.9810cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin
phorbol 12,13-dibutyrate
Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.		1.9710butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
scopolamine hydrobromide
[no description available]		1.9810
ubiquinone
Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.		1.9810
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Anoxia, Brain
[description not available]		03.7721
Acute Confusional Senile Dementia
[description not available]		04.6232
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		09.6232
Acute Brain Injuries
[description not available]		01.9810
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		01.9810
Cerebral Ischemia
[description not available]		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9810
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		01.9810
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.3820